GlaxoSmithKline PLC Q3 2021 Earnings Call Transcript - Thomson StreetEvents

GlaxoSmithKline PLC Q3 2021 Earnings Call Transcript

GlaxoSmithKline PLC Q3 2021 Earnings Call Transcript - Thomson StreetEvents
GlaxoSmithKline PLC Q3 2021 Earnings Call Transcript
Published Oct 27, 2021
19 pages (13671 words) — Published Oct 27, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of GSK.L earnings conference call or presentation 27-Oct-21 1:00pm GMT

  
Brief Excerpt:

...Operator Good afternoon, everyone, and welcome to the analyst call on the GSK Third Quarter 2021 Results. I will now hand you over to Nick Stone, Head of Investor Relations, who will introduce today's session. Nick Stone Thank you, operator. Good morning and good afternoon. As you've just heard, I am Nick Stone, Head of Investor Relations at GSK. It's my pleasure to welcome you to our third quarter 2020 conference call and webcast for investors and analysts. The presentation was posted to gsk.com and was also sent to our distribution list a little bit earlier today. Please turn to Slide 2. This is the usual safe harbor statement, and we'll be making comments on performance using constant exchange rates, or CER. Please turn to Slide 3. This is today's agenda where we'll plan to cover all aspects of our results. The presentation will last approximately 25 minutes in order to maximize the opportunity for questions. (Operator Instructions) Our speakers today are Emma Walmsley, Luke Miels, Deborah...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
GlaxoSmithKline PLC
Ticker
GSK.L
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Two questions, please, on Zejula. Luke, I think you said diagnosis rates, any barriers still around 15% below pre-pandemic level. Are you seeing any signs of improvement here now? And is this something you expect to normalize this year? Or are you going to move into next? Essentially, when do you expect a step change in the Zejula sales growth trajectory? And then just on Benlysta, perhaps a question about any thoughts on why the Phase III BLISS-BELIEVE study failed to show any incremental benefit from the Benlysta mono enzymes?

Table Of Contents

GlaxoSmithKline PLC Q4 2021 Earnings Call Transcript – 2022-02-09 – US$ 54.00 – Edited Transcript of GSK.L earnings conference call or presentation 9-Feb-22 2:00pm GMT

GlaxoSmithKline PLC at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-11 – US$ 54.00 – Edited Transcript of GSK.L presentation 11-Jan-22 12:30pm GMT

GlaxoSmithKline PLC at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript – 2022-01-06 – US$ 54.00 – Edited Transcript of GSK.L presentation 6-Jan-22 1:00pm GMT

GlaxoSmithKline PLC Meet GSK Management: Getting Ahead of HIV Transcript – 2021-11-29 – US$ 54.00 – Edited Transcript of GSK.L corporate analyst meeting</ 29-Nov-21 3:00pm GMT

GlaxoSmithKline PLC Investor Science Event: ASN Kidney Week Transcript – 2021-11-07 – US$ 54.00 – Edited Transcript of GSK.L corporate analyst meeting</ 7-Nov-21 5:00pm GMT

GlaxoSmithKline PLC at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript – 2021-10-06 – US$ 54.00 – Edited Transcript of GSK.L presentation 6-Oct-21 5:00pm GMT

GlaxoSmithKline PLC at Citi BioPharma Conference (Virtual) Transcript – 2021-09-09 – US$ 54.00 – Edited Transcript of GSK.L presentation 9-Sep-21 5:25pm GMT

GlaxoSmithKline PLC Q2 2021 Earnings Call Transcript – 2021-07-28 – US$ 54.00 – Edited Transcript of GSK.L earnings conference call or presentation 28-Jul-21 1:00pm GMT

GlaxoSmithKline PLC Investor Update Transcript – 2021-06-23 – US$ 54.00 – Edited Transcript of GSK.L corporate analyst meeting</ 23-Jun-21 1:00pm GMT

GlaxoSmithKline PLC Q1 2021 Earnings Call Transcript – 2021-04-28 – US$ 54.00 – Edited Transcript of GSK.L earnings conference call or presentation 28-Apr-21 1:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "GlaxoSmithKline PLC Q3 2021 Earnings Call Transcript" Oct 27, 2021. Alacra Store. May 04, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2021-GlaxoSmithKline-PLC-Earnings-Call-T15004022>
  
APA:
Thomson StreetEvents. (2021). GlaxoSmithKline PLC Q3 2021 Earnings Call Transcript Oct 27, 2021. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2021-GlaxoSmithKline-PLC-Earnings-Call-T15004022>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.